The scientists observed that the RNA from the SARS-CoV-2 virus triggered the development of inducible nonclassical monocytes (I-NCMs), which have anti-cancer properties. These immune cells were capable of attacking cancer cells and might be helpful in treating cancers resistant to current therapies.
Dr. Ankit Bharat emphasized, 'This discovery opens up a new avenue for cancer treatment. We specifically saw a response with melanoma, lung, breast and colon cancer.' Future studies may validate these findings in human patients.
The research highlights that the unique immune cells can be pharmacologically stimulated using small molecules. This suggests a potential new therapeutic option for cancer patients, especially those with aggressive forms.
While the study is still in early stages and focused on preclinical animal models, it shows promise that pharmacologically induced immune responses can be harnessed for benefits in advanced cancer treatment.
Collection
[
|
...
]